SC
GBT

Steven Cohen’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Steven Cohen’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-50,000
Closed -$2.76M – 1210
2020
Q3 		$2.76M Buy
+50,000
New +$3.18M 0.01% 662

Other funds holding GBT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Steven Cohen's GBT Position: Q3 2022 in Review

Steven Cohen sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2022, closing a stake of 1,524,485 shares — an estimated $48.7M sold.

Steven Cohen first reported a position in GBT in Q1 2016 and held it in 17 quarters. The position peaked at $72.2M in Q2 2021. 247 funds tracked by Wall St. Rank hold GBT as of Q3 2022.

  • Steven Cohen reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2022 after selling out during the quarter.
  • Steven Cohen sold 1,524,485 Global Blood Therapeutics, Inc. shares in Q3 2022, an estimated $48.7M.
  • Steven Cohen first reported a position in Global Blood Therapeutics, Inc. in Q1 2016 and held it in 17 quarters.
  • Steven Cohen's Global Blood Therapeutics, Inc. position peaked at $72.2M in Q2 2021.
  • 247 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2022.

Based on Point72 Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.